Loading...
XSHE002821
Market cap3.43bUSD
Jan 17, Last price  
73.71CNY
1D
0.96%
1Q
-2.99%
Jan 2017
2.73%
IPO
204.84%
Name

Asymchem Laboratories Tianjin Co Ltd

Chart & Performance

D1W1MN
XSHE:002821 chart
P/E
11.08
P/S
3.21
EPS
6.65
Div Yield, %
2.64%
Shrs. gr., 5y
2.37%
Rev. gr., 5y
33.65%
Revenues
7.83b
-23.70%
405,691,300424,399,200542,757,593716,207,193830,607,6941,103,194,9521,423,033,4121,834,877,6242,459,985,5333,149,689,6754,638,834,17710,255,325,3927,825,190,298
Net income
2.27b
-31.28%
65,372,50060,251,40074,729,476101,791,578153,545,023252,735,199341,287,654428,295,474553,863,836722,091,3601,069,273,5773,301,635,0192,268,810,444
CFO
3.55b
+8.00%
25,883,50034,384,900105,917,363127,045,751256,994,132278,355,646196,400,310415,060,930600,867,843569,291,589113,150,1213,286,910,7053,549,728,383
Dividend
Jun 28, 20241.8 CNY/sh
Earnings
Jun 06, 2025

Profile

Asymchem Laboratories (Tianjin) Co., Ltd. provides contract development and manufacturing organization services in Mainland China and internationally. The company offers drug research and development, and manufacturing services for pharmaceutical and biotech companies. Its solutions range from early clinical stage to commercial stage, including research and development, and cGMP production of advanced intermediates, active pharmaceutical ingredients, and formulations, as well as clinical research services. The company also engages in the provision of pharmaceutical analysis and testing services; sale, wholesale, and retail of drugs; and pharmaceutical science and technology development activities. The company was founded in 1999 and is headquartered in Tianjin, China.
URL
https://www.asymchem.com.cn/
IPO date
Nov 18, 2016
Employees
9,719
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
7,825,190
-23.70%
10,255,325
121.08%
Cost of revenue
4,898,684
6,492,121
Unusual Expense (Income)
NOPBT
2,926,506
3,763,204
NOPBT Margin
37.40%
36.70%
Operating Taxes
306,310
430,314
Tax Rate
10.47%
11.43%
NOPAT
2,620,196
3,332,891
Net income
2,268,810
-31.28%
3,301,635
208.77%
Dividends
(663,897)
(211,272)
Dividend yield
1.58%
0.39%
Proceeds from repurchase of equity
(9,317)
BB yield
0.02%
Debt
Debt current
12,228
28,487
Long-term debt
212,972
219,719
Deferred revenue
232,599
168,121
Other long-term liabilities
1
Net debt
(9,657,752)
(7,192,451)
Cash flow
Cash from operating activities
3,549,728
3,286,911
CAPEX
(1,241,610)
Cash from investing activities
(2,890,264)
Cash from financing activities
(542,029)
FCF
2,865,501
1,443,746
Balance
Cash
9,015,765
7,440,656
Long term investments
867,186
Excess cash
9,491,692
6,927,890
Stockholders' equity
8,159,656
6,572,500
Invested Capital
9,701,636
9,311,618
ROIC
27.56%
41.55%
ROCE
16.28%
23.56%
EV
Common stock shares outstanding
362,430
366,848
Price
116.12
-21.54%
148.00
-65.98%
Market cap
42,085,346
-22.49%
54,293,554
-63.43%
EV
32,457,857
48,097,562
EBITDA
3,390,449
4,104,941
EV/EBITDA
9.57
11.72
Interest
6,322
10,529
Interest/NOPBT
0.22%
0.28%